Radiotherapy and stereotactic radiotherapy for multifocal intracranial and intramedullary Rosai–Dorfman disease

Q4 Immunology and Microbiology Clinical and Experimental Neuroimmunology Pub Date : 2024-04-11 DOI:10.1111/cen3.12785

Salvatore D'Oria, Martina Rossitto, David Giraldi, Vincenzo Fanelli, Ilaria Bonaparte, Maria Paola Ciliberti, Alba Fiorentino

{"title":"Radiotherapy and stereotactic radiotherapy for multifocal intracranial and intramedullary Rosai–Dorfman disease","authors":"Salvatore D'Oria, Martina Rossitto, David Giraldi, Vincenzo Fanelli, Ilaria Bonaparte, Maria Paola Ciliberti, Alba Fiorentino","doi":"10.1111/cen3.12785","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>We present a case of a 51-year-old man affected by Rosai–Dorfman disease with multiple disseminated intraparenchymal and a single spinal cord localization, presenting with dysphasia and paraparesis.</p>\n </section>\n \n <section>\n \n <h3> Case Presentation</h3>\n \n <p>The patient elected to receive medical steroidal therapy and two radiotherapy cycles. Steroids allowed initial regression of some lesions, while radiotherapy constituted an optimal maintenance treatment. At 6-year follow up, the patient did not develop any new neurological damage in respect to baseline.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Adjuvant therapy with radiotherapy and steroidal therapy is a valid option in multicentric Rosai–Dorfman disease patients not eligible for surgery.</p>\n </section>\n </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.12785","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

Abstract

Background

We present a case of a 51-year-old man affected by Rosai–Dorfman disease with multiple disseminated intraparenchymal and a single spinal cord localization, presenting with dysphasia and paraparesis.

Case Presentation

The patient elected to receive medical steroidal therapy and two radiotherapy cycles. Steroids allowed initial regression of some lesions, while radiotherapy constituted an optimal maintenance treatment. At 6-year follow up, the patient did not develop any new neurological damage in respect to baseline.

Conclusions

Adjuvant therapy with radiotherapy and steroidal therapy is a valid option in multicentric Rosai–Dorfman disease patients not eligible for surgery.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

多灶性颅内和髓内罗赛-多夫曼病的放射治疗和立体定向放射治疗

我们介绍了一例51岁男性罗赛-多夫曼病患者的病例，他患有多发性播散性骨髓内病变和单发脊髓病变，并伴有失语和截瘫。类固醇可使部分病灶初步消退，而放疗则是最佳的维持治疗方法。在6年的随访中，与基线相比，患者没有出现任何新的神经损伤。对于不符合手术条件的多中心罗赛-多夫曼病患者来说，放疗和类固醇疗法是一种有效的辅助治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Experimental Neuroimmunology Immunology and Microbiology-Immunology and Microbiology (miscellaneous)

CiteScore

1.60

自引率

0.00%

发文量